Summary: "The vector of anti-CD37 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD37. The T cells are genetically modified through transduction with a vector expressing scFv of anti-CD37 antibody linked to a CD28 transmembrane domain/ endodomain and FcεRIγ signaling domains. And the vector product was designed for the treatment of B cell malignancies, such as chronic lymphocytic leukemia (CLL), B cell non-Hodgkin lymphoma (B cell NHL), hairy cell leukemia (HCL), acute lymphoblastic leukemia (ALL) and lymphoplasmacytic lymphoma. https://www.creative-biolabs.com/car-t/pcdcar1-cd37-h-28fc%CE%B5ri%CE%B3-t-136.htm"
Description: "The vector of anti-CD37 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CD37. The T cells are genetically modified through transduction with a vector expressing scFv of anti-CD37 antibody linked to a CD28 transmembrane domain/ endodomain and FcεRIγ signaling domains. And the vector product was designed for the treatment of B cell malignancies, such as chronic lymphocytic leukemia (CLL), B cell non-Hodgkin lymphoma (B cell NHL), hairy cell leukemia (HCL), acute lymphoblastic leukemia (ALL) and lymphoplasmacytic lymphoma. https://www.creative-biolabs.com/car-t/pcdcar1-cd37-h-28fc%CE%B5ri%CE%B3-t-136.htm"